Mannitol and Sorbitol Infusion

Trade Name: —
Generic Name: Mannitol 17.5% + Sorbitol 2.5% Injection Solution

Dosage Form:
Intravenous infusion solution containing Mannitol 17.5% w/v and Sorbitol 2.5% w/v.

Packaging Form:
IV infusion bag made of PVC with an injection port and infusion port, free from antibacterial preservatives.
PVC bags comply with B. Braun EXCEL or Hospira standards, designed with dual ports for easy injection and transfer, puncture-resistant, lightweight, and portable for emergency use.
Free from DEHP and latex to minimize toxicity.

Pharmacological Classification:
Osmotic diuretic and osmotic laxative.

Indications:

• Treatment of increased intracranial pressure (ICP) due to cerebral edema or brain swelling.
• Reduction of intraocular pressure (IOP) in acute glaucoma.
• Osmotic diuresis in mild renal insufficiency or intoxications.
• In acute renal failure associated with surgical procedures or shock.

Dosage and Administration:
Dosage depends on the patient’s condition and must be determined by a specialist physician.

Contraindications:
Anuria, pulmonary edema, intracranial hemorrhage, severe dehydration, hypersensitivity to mannitol or sorbitol.

Precautions:
Use with caution in renal failure, hepatic insufficiency, heart failure, pulmonary edema, and elevated intracranial pressure.

Drug Interactions:

• Concurrent use with diuretics may lead to excessive diuresis.
• Combined use with ACE inhibitors may cause severe hypotension and renal impairment.
• Co-administration with digoxin increases the risk of digoxin toxicity due to hypokalemia, leading to cardiac arrhythmias.
• Concurrent use with nephrotoxic or neurotoxic agents may enhance kidney damage.

Side Effects:
Electrolyte disturbances (hyponatremia, hypokalemia), nausea, vomiting, headache, increased or decreased blood pressure.

Lactation:
Due to the low molecular weight of mannitol, it may be excreted in breast milk. Use during lactation only under medical supervision.

Warnings:
Careful monitoring of blood volume, osmolarity, pressure, and electrolytes is essential.
Use with great caution in cardiac or renal patients.
If crystallization occurs, warm the solution to 70°C, cool, and inspect before use.
Use immediately after opening; discard any remaining solution.

Storage Conditions:
Store at 15–30°C, protect from freezing (freezing increases crystallization risk), and keep away from direct sunlight.
Do not use cloudy solutions or those containing dissolved crystals.
Use a filtered IV set during administration.

Dispensing Condition:
Prescription only.

Manufacturer:
Parsawa Injectable Solutions Factory
Industrial City, Phase 3, Sosan 5, Herat, Afghanistan